[
    [
        {
            "time": "2018-11-01",
            "original_text": "复星医药控股子公司Grand Pharma拟在印度证交所和孟买证交所上市 合景泰富10月预售额升123.6%至101.28亿元",
            "features": {
                "keywords": [
                    "复星医药",
                    "Grand Pharma",
                    "印度上市",
                    "合景泰富",
                    "预售额"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "房地产"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药控股子公司Grand Pharma拟在印度证交所和孟买证交所上市 合景泰富10月预售额升123.6%至101.28亿元",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-11-01",
            "original_text": "下周333亿市值限售股解禁，环比减少36.41% 解禁",
            "features": {
                "keywords": [
                    "限售股",
                    "解禁",
                    "市值"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "全市场"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "下周333亿市值限售股解禁，环比减少36.41% 解禁",
                "Correlation": 5,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-11-01",
            "original_text": "复星医药：第八届董事会第八次会议（临时会议）决议公告",
            "features": {
                "keywords": [
                    "复星医药",
                    "董事会",
                    "决议公告"
                ],
                "sentiment_score": 0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药：第八届董事会第八次会议（临时会议）决议公告",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-11-01",
            "original_text": "A股头条之上市公司（11.1）",
            "features": {
                "keywords": [
                    "A股",
                    "上市公司"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "全市场"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "A股头条之上市公司（11.1）",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 4,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-11-01",
            "original_text": "复星医药一控股子公司拟境外上市",
            "features": {
                "keywords": [
                    "复星医药",
                    "控股子公司",
                    "境外上市"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药一控股子公司拟境外上市",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-11-01",
            "original_text": "复星医药(02196.HK)子公司禅城医院向深圳复星健康注资1040.8万元持股51%",
            "features": {
                "keywords": [
                    "复星医药",
                    "禅城医院",
                    "注资",
                    "深圳复星健康"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药(02196.HK)子公司禅城医院向深圳复星健康注资1040.8万元持股51%",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-11-01",
            "original_text": "实锤：4+7中选药采购量扩增6倍，9000药品将遭临床替代",
            "features": {
                "keywords": [
                    "4+7",
                    "药品采购",
                    "临床替代"
                ],
                "sentiment_score": -0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "实锤：4+7中选药采购量扩增6倍，9000药品将遭临床替代",
                "Correlation": 6,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-11-01",
            "original_text": "[复星医药]19Q3季报点评：扣非增速较高，创新转型稳步推进",
            "features": {
                "keywords": [
                    "复星医药",
                    "季报",
                    "扣非增速",
                    "创新转型"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "[复星医药]19Q3季报点评：扣非增速较高，创新转型稳步推进",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-11-01",
            "original_text": "复星医药(02196-HK)子公司禪城医院开拓互联网的新医疗服务",
            "features": {
                "keywords": [
                    "复星医药",
                    "禪城医院",
                    "互联网医疗"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "互联网"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药(02196-HK)子公司禪城医院开拓互联网的新医疗服务",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-11-01",
            "original_text": "[异动股]青蒿素板块拉升，浙江医药(600216-CN)涨停",
            "features": {
                "keywords": [
                    "青蒿素",
                    "浙江医药",
                    "涨停"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[异动股]青蒿素板块拉升，浙江医药(600216-CN)涨停",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-11-01",
            "original_text": "恒指低开0.37% 地产代理板块领跌",
            "features": {
                "keywords": [
                    "恒指",
                    "低开",
                    "地产代理",
                    "领跌"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "房地产",
                    "全市场"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "恒指低开0.37% 地产代理板块领跌",
                "Correlation": 2,
                "Sentiment": 3,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        }
    ]
]